Sort
15,842 grants matching “pancreatic cancer”
Targeting Acquired Resistance in KRAS Driven Cancers
$420,385Wantong Yao · University Of Tx Md Anderson Can Ctr · R37 · FY2024 · CA
AKT2 Function and Oncogenic Activity
$420,343Fox Chase Cancer Center · R01 · FY2005 · CA
Harnessing the therapeutic potential of histotripsy focused ultrasound-induced immunogenic cancer cell death
$420,313Clifford Cho · University Of Michigan At Ann Arbor · R01 · FY2023 · CA
Dynamic requirements of Ras signaling during cancer
$420,122Christopher M Counter · Duke University · R01 · FY2011 · CA
Exploitation of RAS signaling to develop therapy and early detection strategies for PDA
$420,093Rolf A Brekken · Ut Southwestern Medical Center · R01 · FY2019 · CA
Core 1: Tumor and Microenvironment Heterogeneity Core (TMH Core)
$420,065Susan M Kaech · Salk Institute For Biological Studies · P01 · FY2025 · CA
Nanomedicine of Hedgehog and AKT/ERK Dual Inhibitors for Pancreatic Cancer
$420,006Ram I Mahato · University Of Nebraska Medical Center · R01 · FY2024 · CA
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
$420,000Bhupendra S Kaphalia · University Of Texas Med Br Galveston · R21 · FY2023 · AA
Basis for Lymphomagenesis in Akt2 Transgenic Mice
$419,987Joseph Robert Testa · Fox Chase Cancer Center · R01 · FY2011 · CA
Optimizing the Treatment of Pancreatic Adenocarcinoma
$419,924Chin Hur · Columbia University Health Sciences · R01 · FY2018 · CA
Project 1: Improving Immunotherapy in pancreatic NETs
$419,863Dawn E Quelle · University Of Iowa · P50 · FY2025 · CA
DNA Nanostructures for High-Throughput Cryo-EM Studies of Small Macromolecules
$419,826Shawn M Douglas · University Of California, San Francisco · R35 · FY2023 · GM
Combining Irreversible Electroporation with Immunotherapy for the Systemic Treatment of Pancreatic Cancer
$419,732Rebekah White · University Of California, San Diego · R01 · FY2021 · CA
Mouse Models for Tumor Progression and Maintenance
$419,711Harold E Varmus · Sloan-Kettering Inst Can Research · P01 · FY2009 · CA
Targeting Dectin-2 on Tumor-associated Macrophages for the Treatment of Cancer
$419,692Edgar G. Engleman · Stanford University · R01 · FY2022 · CA
Whole Genome Scan in the Pancreatic Cancer Cohort Consortium (PanScan)
$419,644Rachael Solomon · Division Of Cancer Epidemiology And Genetics · ZIA · FY2018 · CA
Preventing tumor relapse with biomaterial-supported lymphocyte implants
$419,624Matthias Stephan · Fred Hutchinson Cancer Research Center · R01 · FY2015 · CA
Molecular Epidemiology of Pancreatic Cancer
$419,539Donghui Li · University Of Tx Md Anderson Can Ctr · R01 · FY2007 · CA
Molecular Magnetic Resonance Imaging of Inflammation
$419,456Eric Michael Gale · Massachusetts General Hospital · R01 · FY2022 · DK
Damage Sensing and Growth Control in the Drosophila Gut
$419,375Bruce A Edgar · University Of Utah · R01 · FY2018 · GM
Directing the metabolic fate of CAR T cells
$419,337Carl H. June · University Of Pennsylvania · R01 · FY2019 · CA
Antibody-dual drug conjugates for eradicating triple-negative breast cancer with heterogeneity
$419,275Kyoji Tsuchikama · University Of Texas Hlth Sci Ctr Houston · R01 · FY2025 · CA
Therapeutic Potential of a Novel MGMT-Dependent DNA Interstrand Crosslinking Agent in the Treatment of DNA Repair Deficient Cancer
$418,750Susan E Gueble · Yale University · DP5 · FY2023 · OD
Therapeutic Potential of a Novel MGMT-Dependent DNA Interstrand Crosslinking Agent in the Treatment of DNA Repair Deficient Cancer
$418,750Susan E Gueble · Yale University · DP5 · FY2025 · OD
Therapeutic Potential of a Novel MGMT-Dependent DNA Interstrand Crosslinking Agent in the Treatment of DNA Repair Deficient Cancer
$418,750Susan E Gueble · Yale University · DP5 · FY2024 · OD